[Morphological features of immune-related cutaneous adverse events associated with anti-PD-1/PD-L1 cancer immunotherapy].
To study the morphological patterns of immune-related cutaneous lesions (irCLs) that occur during antitumor immunotherapy in cancer patients.
The study included 48 patients with the following nosology: malignant neoplasms of the skin and soft tissues - 20 patients (41.7%), malignant neoplasms of the genitourinary system - 13 (27%), malignant neoplasms of the lungs and bronchi - 9 (18.8%), malignant neoplasms of the upper respiratory tract - 5 (10.4%), malignant neoplasms of the gastrointestinal tract - 1 (2.1%), with immune-mediated skin lesions during treatment with pembrolizumab - 25 (52.1%), nivolumab - 18 (37.5%), prolgolimab - 4 (8.3%), avelumab - 1 (2.1%).
Among the irCLs in the study cohort, lichenoid - 14 (29.2%) cases and psoriasiform - 11 cases (22.9%) were predominant, while other morphological variants were significantly less common. IrCL morphologically mimic classic dermatoses, but have distinctive features indicating their drug-induced, immune-related nature.
The study demonstrated that irCLs are clinically significant complications of PD-1/PD-L1 inhibitor therapy. Histological analysis confirmed their immunoinflammatory nature and revealed characteristic morphological changes, emphasizing the importance of routine skin biopsies for optimal patient management.
The study included 48 patients with the following nosology: malignant neoplasms of the skin and soft tissues - 20 patients (41.7%), malignant neoplasms of the genitourinary system - 13 (27%), malignant neoplasms of the lungs and bronchi - 9 (18.8%), malignant neoplasms of the upper respiratory tract - 5 (10.4%), malignant neoplasms of the gastrointestinal tract - 1 (2.1%), with immune-mediated skin lesions during treatment with pembrolizumab - 25 (52.1%), nivolumab - 18 (37.5%), prolgolimab - 4 (8.3%), avelumab - 1 (2.1%).
Among the irCLs in the study cohort, lichenoid - 14 (29.2%) cases and psoriasiform - 11 cases (22.9%) were predominant, while other morphological variants were significantly less common. IrCL morphologically mimic classic dermatoses, but have distinctive features indicating their drug-induced, immune-related nature.
The study demonstrated that irCLs are clinically significant complications of PD-1/PD-L1 inhibitor therapy. Histological analysis confirmed their immunoinflammatory nature and revealed characteristic morphological changes, emphasizing the importance of routine skin biopsies for optimal patient management.
Authors
Syryseva Syryseva, Shatokhina Shatokhina, Pokataev Pokataev, Bobyreva Bobyreva, Danilova Danilova
View on Pubmed